Wed, 31st Aug 2016 14:56
(ShareCast News) - AstraZeneca, the UK's second-biggest drug developer, will this week outline its next big hope in the battle against cancer by unveiling new data on a class of treatments, known as DNA damage response (DDR) medicines, at a conference in Chicago. The drugs work by stopping cancerous
Read more(ShareCast News) - Exova Group: Goldman Sachs reiterates buy with a 195p target. Grainger: Jefferies retains buy with a 215p target. Thomas Cook: JP Morgan keeps at neutral with a 90p target and Goldman Sachs reiterates sell with a target price of 72p. Serco Group: JP Morgan reiterates neutral wit
Read more(ShareCast News) - Exova expects modest full-year organic growth at constant currency rates and earnings in line with previous guidance, adjusted for the just-announced sale of its Food, Water and Pharmaceutical (FWP) business in the UK and Ireland. "Given the strong pipeline, we expect our mergers
Read more